Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 8/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166151 | 0.90 | HCRTR2 (0.57) | HCRTR2HCRTR1TP53HDAC1ACHE | |
| SCHEMBL10166866 | 0.90 | HCRTR2 (0.58) | HCRTR2HCRTR1TP53HDAC1ACHE | |
| SCHEMBL10166451 | 0.90 | TP53 (0.51) | HCRTR2HCRTR1TP53HDAC1ACHE | |
| SCHEMBL667539 | 0.86 | HCRTR2 (0.78) | HCRTR2HCRTR1TP53HDAC1THRB | |
| SCHEMBL10165791 | 0.84 | TP53 (0.51) | HCRTR2TP53HDAC1ACHEKLKB1 | |
| SCHEMBL667753 | 0.83 | HCRTR2 (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL667759 | 0.77 | HCRTR2 (0.80) | HCRTR2HCRTR1TP53HDAC1LMNA | |
| SCHEMBL667564 | 0.77 | HCRTR2 (0.89) | HCRTR2HCRTR1TP53HDAC1LMNA | |
| SCHEMBL667875 | 0.74 | HCRTR2 (1.00) | HCRTR2HCRTR1TP53HDAC1LMNA | |
| SCHEMBL667392 | 0.74 | KCNK3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885HCRTR1 2/4885TP53 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.